Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Praluent is most often covered alongside Amgen, which appears in 1 of these 1 story. The tracked stories average 132 original sources each. Praluent appears in 1 tracked Healthcare story from July 16, 2026.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Praluent is most often covered alongside Amgen, which appears in 1 of these 1 story. The tracked stories average 132 original sources each. Praluent appears in 1 tracked Healthcare story from July 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Praluent. Shared-story counts are live from our verified record — not editorial picks.
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Praluent is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
